PHAXIAM Therapeutics S.A. (PHXM)
Market Cap | 28.90M |
Revenue (ttm) | 6.56M |
Net Income (ttm) | -12.53M |
Shares Out | 6.40M |
EPS (ttm) | -3.84 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 902 |
Open | 3.060 |
Previous Close | 3.270 |
Day's Range | 3.050 - 3.100 |
52-Week Range | 2.500 - 13.000 |
Beta | 1.96 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | May 7, 2024 |
About PHXM
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thir... [Read more]
Financial Performance
In 2022, PHXM's revenue was 31.00 million, an increase of 641.58% compared to the previous year's 4.18 million. Losses were -228,000, -99.58% less than in 2021.
Financial numbers in EUR Financial StatementsNews
PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus
Lyon (France) and Cambridge (MA, US), April 15, 2024 – 7:30am CEST - PHAXIAM Therapeutics (Nasdaq & Euronext: FR0011471135), today announces the enrolment of the 1st patient in the phase 1 clinical st...
PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)
Lyon (France) and Cambridge (MA, US), 5 April 2024 – 6:00pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resi...
PHAXIAM Announces 2023 Full-Year Results and Provides Business Update
Conference call and webcast (English) on Thursday, March 21, 2024
PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
Lyon (France) and Cambridge (MA, US), March 11, 2024, at 07:00am CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resis...
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024
Lyon (France) and Cambridge (MA, US), January 18, 2024, at 10:05pm CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and res...
PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023
Conference call and webcast (English) on Wednesday, November 15, 2023 at 8:30am ET / 2:30pm CET Ambitious clinical development strategy progressing to create a global phage therapy leader in high-valu...
PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus
Lyon (France) et Cambridge (MA, US), October 24, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for resistant bac...
TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendation
Lyon (France) et Cambridge (MA, US), October 23, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for resistant bac...
PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains
PHAXIAM Therapeutics announces high coverage performance of its two anti- Staphylococcus aureus phages over clinical strains.
PHAXIAM Receives Compliance Notice from Nasdaq
PHAXIAM Receives Compliance Notice from Nasdaq Lyon (France) et Cambridge (MA, US), October 4, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), today announced that it has rece...
PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration
Strategic research partnership between PHAXIAM Therapeutics and Vetophage, a biotechnology company specialized in veterinary phage therapy. Combining expertise in the research of new phages and phage ...
Rapport Financier Semestriel 30 Juin 2023 PHAXIAM
Rapport Financier Semestriel 30 Juin 2023 PHAXIAM.
PHAXIAM Provides Business and Financial Update For the First Half of 2023
Formation of PHAXIAM Therapeutics effective as of June 23, 2023, to create a global leader in phage therapies for high-value indications. Ambitious strategy to develop value-creating clinical and regu...
PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target
PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae , a new resistant and aggressive bacterial target
PHAXIAM Therapeutics announces the completion of its reverse share split
PRESS RELEASE PHAXIAM Therapeutics announces the completion of its reverse share split Lyon (France) and Cambridge (MA, US) , September 18 th , 2023 - PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM) (...
PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences
P HAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences
PHAXIAM Therapeutics announces a reverse share split of its shares
PRESS RELEASE P HAXIAM Therapeutics announces a reverse share split of its shares Reverse share split by the exchange of ten (10) existing shares with a par value of ten-euro cents (€0.10) for one (1)...
Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM
Lyon (France) and Cambridge (MA, US), June 28, 2023 - Phaxiam Therapeutics (Nasdaq & Euronext: FR0011471135), announces change of the mnemonic code of its share from ERYP to PHXM, following the merger...
ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics
ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics Merger approved with large majority by the shareholders of both companies New governance structure implemented Ambition t...
ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder's Meeting held on June 23, 2023
Lyon (France), June 23, 2023 – ERYTECH Pharma (Euronext Paris & Nasdaq: ERYP) announced today that all resolutions for which the Board of Directors recommended a vote in favor, including the approval ...
ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit
Cambridge, MA (U.S.) and Lyon (France), June 20, 2023 – ERYTECH Pharma (Euronext Paris and Nasdaq: ERYP) announces the filing of a new lawsuit by Akkadian Partners.
ERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharma
Cambridge, MA (U.S.) and Lyon (France), June 14, 2023, 8:00 pm CEST – ERYTECH Pharma (Nasdaq & Euronext: ERYP), announced today that the Lyon Commercial Court has rejected Akkadian's request to postpo...
ERYTECH Responds to Akkadian's Disinformation
Cambridge, MA (U.S.) and Lyon (France), June 12, 2023, 7:00 am CEST – ERYTECH Pharma (Nasdaq & Euronext: ERYP), today reacts to a series of disinformation attempts by Akkadian Partners to try and dest...
ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes
ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes